Skip to main content

Table 1 Patient demographics and Gene selection in Test set

From: A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

Variable

Test set

  

Patients

N

16

  

Age

Median

60.6

  
 

Range

24-71

  
  

N (%)

  

Best response

CR

3 (18.8%)

  
 

PR

9 (56.2%)

  
 

SD

2 (12.6%)

  
 

PD

2 (12.6%)

  

Histological Grade

1-2

10 (62.6%)

  
 

3-4

5 (31.2%)

  

Gender

Female

8 (50%)

  
 

Male

8 (50%)

  

Progressive disease within 8 months

 

6 (37.6%)

  

Microarray analysis: Gene selection

Gene

Name

EntrezID

Fold change in 8-month Progression-free cohort

FDR

KLF12

Kruppel-like factor 12

11278

1.87

0.092

AGR2

Anterior gradient homolog 2 (Xenopus laevis)

10551

0.62

0.092

ALDH6A1

Aldehyde dehydrogenase 6 family, member A1

4329

0.63

0.092

MCM5

Minichromosome maintenance complex component 5

4174

0.48

0.157

TFF2

Trefoil factor 2

7032

0.45

0.002